Pacira BioSciences, Inc. PCRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.92M+78.1% | $1.64M-69.9% | $5.43M+212% | -$4.85M-201% | $4.81M— | ||
| $21.33M-0.1% | $21.34M+0.7% | $21.19M-22.4% | $27.32M+29.1% | $21.17M-0.4% | ||
| $13.54M+0.3% | $13.5M-3.4% | $13.98M-9.7% | $15.47M+6.3% | $14.55M+18.6% | ||
| $1.73M— | —— | $8.07M+973% | $752K-46.2% | $1.4M-60.2% | ||
| $577K-14.8% | $677K+8.1% | $626K-26.3% | $849K-2.1% | $867K-7.6% | ||
| $1.57M-82.2% | $8.8M+881% | $897K-90.7% | $9.61M+212% | -$8.56M-168% | ||
| -$2.49M— | —— | $9.51M-33.9% | $14.4M+70.0% | $8.47M-36.9% | ||
| -$936K+68.0% | -$2.93M+75.6% | -$12.01M-275% | $6.88M+179% | $2.46M— | ||
| -$10.31M-174% | $14M+85.9% | $7.53M+139% | -$19.38M-512% | $4.7M— | ||
| $4.54M— | —— | —— | $13.43M+158% | $5.2M+181% | ||
| $3.29M— | —— | —— | $9.82M+808% | $1.08M-72.3% | ||
| -$2.28M— | —— | —— | -$357K+86.7% | -$2.68M— | ||
| $25.68M-41.2% | $43.69M-28.2% | $60.83M+406% | $12.01M-66.1% | $35.46M+7.0% | ||
| $2.72M+1,150% | $218K-94.4% | $3.87M+43.5% | $2.7M-68.4% | $8.55M+304% | ||
| $335K— | —— | —— | —— | $16.7M— | ||
| $0-100% | $27.59M-28.8% | $38.77M+667% | $5.06M-92.7% | $69.63M+54.1% | ||
| $22.5M-52.3% | $47.14M-45.3% | $86.25M+21.2% | $71.17M+2.8% | $69.25M+47.5% | ||
| $19.44M+0.6% | $19.33M-55.7% | $43.61M-29.8% | $62.16M+343% | -$25.63M-6,864% | ||
| $50.05M+3.7% | $48.25M-3.6% | $50.04M0.0% | $50.04M— | $0-100% | ||
| $5M0.0% | $5M— | —— | —— | $0— | ||
| $2K-99.6% | $490K— | —— | —— | $0— | ||
| $4.36M+2,945% | $143K+1,688% | $8K-99.8% | $5.29M+2,820% | $181K+135% | ||
| -$59.4M-15.0% | -$51.65M+79.9% | -$257.48M-348% | -$57.51M-1,821% | -$2.99M— | ||
| $38K+109% | -$414K-411% | $133K-34.8% | $204K— | $0— | ||
| -$14.24M— | $0+100% | -$152.9M-1,006% | $16.87M+147% | $6.84M-77.8% | ||
| $1.6M-67.1% | $4.85M+79.2% | $2.7M-45.6% | $4.97M+83.1% | $2.72M-48.1% | ||
| $50K— | —— | $711K-91.1% | $7.95M+2,679% | $286K-80.2% | ||
| $570K— | —— | —— | —— | $1.91M+3.0% | ||
| $577K— | —— | —— | —— | $867K+7.6% | ||
| -$2.28M— | —— | —— | -$357K+86.7% | -$2.68M— | ||
| —— | $0— | $0— | $0— | $0+100% | ||
| —— | $1.71M0.0% | $1.71M0.0% | $1.71M0.0% | $1.71M-52.5% | ||
| $4.54M— | —— | —— | $13.43M+158% | $5.2M+181% | ||
| $0— | —— | —— | —— | -$5.89M-2,137% | ||
| $0-100% | $27.59M-28.8% | $38.77M+667% | $5.06M-92.7% | $69.63M+54.1% | ||
| $22.5M-52.3% | $47.14M-45.3% | $86.25M+21.2% | $71.17M+2.8% | $69.25M+47.5% | ||
| $0— | —— | —— | —— | $2.81M— | ||
| $1.36M+287% | $352K— | —— | $664K-13.4% | $767K-85.1% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $448K0.0% | $448K0.0% | $448K0.0% | $448K— | ||
| $50K— | —— | $711K-91.1% | $7.95M+2,679% | $286K— | ||
| $22.96M-47.2% | $43.47M-23.7% | $56.96M+512% | $9.32M-65.4% | $26.91M-13.2% | ||
| $22.96M-47.2% | $43.47M-23.7% | $56.96M+512% | $9.32M-65.4% | $26.91M-13.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pacira BioSciences, Inc. generate?
- Pacira BioSciences, Inc. (PCRX) generated $142.2M in operating cash flow over the trailing twelve months.
- What is Pacira BioSciences, Inc.'s free cash flow?
- After $9.5M of capital expenditures, Pacira BioSciences, Inc.'s free cash flow was $132.7M over the trailing twelve months, down 16.8% year over year.
- Where does Pacira BioSciences, Inc.'s cash flow data come from?
- Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
